Psychiatry and Evidence-based Medicine
DOI:
https://doi.org/10.36489/saudecoletiva.2025v16i103p18300-18311Keywords:
Evidence-based medicine, Pathologization of life, Psychiatry, Human healthAbstract
Evidence-Based Medicine (EBM) emerged in the 1990s to make medical practice more scientific, replacing decisions based on authority with choices based on empirical data and rigorous studies. Defined as the judicious use of the best available evidence, EBM proposes to integrate scientific research, clinical experience and patient values, promoting shared decisions and reducing errors. Despite its positive impact, it faces criticism regarding the influence of economic and ideological interests, especially in psychiatry, where it can contribute to the pathologization of life. The article concludes that a return to EBM’s original critical spirit is needed, with more rigor and reflection when evaluating evidence, particularly in mental health.
References
Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, R. B., & Richardson, W. S. (1996). Evidence based medicine: What it is and what it isn’t. BMJ, 312(7023), 71–72. https://doi.org/10.1136/bmj.312.7023.71 DOI: https://doi.org/10.1136/bmj.312.7023.71
GRADE Working Group. (2011). GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 64(4), 383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026 DOI: https://doi.org/10.1016/j.jclinepi.2010.04.026
Djulbegovic, B., & Gordon, G. H. (2017). Progress in evidence-based medicine: A quarter century on. The Lancet, 390(10092), 415–423. https://doi.org/10.1016/S0140-6736(16)31592-6 DOI: https://doi.org/10.1016/S0140-6736(16)31592-6
Freddi, G., & Romàn-Pumar, J. L. (2011). Evidence-based medicine: What it can and cannot do. Annali dell'Istituto Superiore di Sanità, 47(1), 22–25. https://doi.org/10.4415/ANN_11_01_05
Burns, P. B., Rohrich, R. J., & Chung, K. C. (2011). The levels of evidence and their role in evidence-based medicine. Plastic and Reconstructive Surgery, 128(1), 305–310. https://doi.org/10.1097/PRS.0b013e318219c171 DOI: https://doi.org/10.1097/PRS.0b013e318219c171
Holmes, D., Murray, S. J., Perron, A., & Rail, G. (2006). Deconstructing the evidence-based discourse in health sciences: Truth, power and fascism. International Journal of Evidence-Based Healthcare, 4(3), 180–186. https://doi.org/10.1111/j.1479-6988.2006.00041.x DOI: https://doi.org/10.1097/01258363-200609000-00003
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252–260. https://doi.org/10.1056/NEJMsa065779 DOI: https://doi.org/10.1056/NEJMsa065779
Stip, E. (2002). Happy birthday neuroleptics! 50 years later: La folie du doute. European Psychiatry, 17(3), 115–119. https://doi.org/10.1016/S0924-9338(02)00639-6 DOI: https://doi.org/10.1016/S0924-9338(02)00639-9
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., ... & Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), 1139–1151. https://doi.org/10.1056/NEJMoa0905561 DOI: https://doi.org/10.1056/NEJMoa0905561
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45. https://doi.org/10.1371/journal.pmed.0050045 DOI: https://doi.org/10.1371/journal.pmed.0050045
Resende, M. S., Pontes, S., & Calazans, R. (2015). O DSM-5 e suas implicações no processo de medicalização da existência. Psicologia em Revista, 21(3), 534–546. https://doi.org/10.5752/P.1678-9563.2015v21n3p534 DOI: https://doi.org/10.5752/P.1678-9523.2015V21N3P534
Stahl, S. M. (2014). Psicofarmacologia: Bases neurocientíficas e aplicações práticas (4ª ed.). Guanabara Koogan.
Oberlander, V. C., Xu, X., Chini, M., & Hanganu-Opatz, I. L. (2019). Developmental dysfunction of prefrontal-hippocampal networks in mouse models of mental illness. European Journal of Neuroscience, 50(6), 3072–3084. https://doi.org/10.1111/ejn.14466 DOI: https://doi.org/10.1111/ejn.14436
Whitaker, R. (2017). Anatomia de uma epidemia. Editora Fiocruz. DOI: https://doi.org/10.7476/9786557082324
Kirsch, I. (2019). The emperor’s new drugs: Exploding the antidepressant myth (2nd ed.). Basic Books.
Furukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., ... & Salanti, G. (2016). Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. BMJ Open, 6(1), e009912. https://doi.org/10.1136/bmjopen-2015-009912 DOI: https://doi.org/10.1136/bmjopen-2015-009912
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303(1), 47–53. https://doi.org/10.1001/jama.2009.1943 DOI: https://doi.org/10.1001/jama.2009.1943
De Camargo, K. R. (2010). A economia política da produção e difusão do conhecimento biomédico. In S. Caponi, M. Verdi, F. S. Brzozowski, & F. Hellmann (Orgs.), Medicalização da vida: Ética, saúde pública e indústria farmacêutica (pp. 45–62). Editora Unisul.
Greene, E. M. (2019). The mental health industrial complex: A study in three cases. Journal of Humanistic Psychology, 63(1), 84–102. https://doi.org/10.1177/0022167819830516 DOI: https://doi.org/10.1177/0022167819830516
Fond, G., Gavaret, M., Vidal, C., Brunel, L., Riveline, J.-P., Micoulaud-Franchi, J.-A., ... & Boyer, L. (2020). Pharmaceutical industry marketing strategies influencing prescribing trends in psychiatry: A 10-year prospective study in France. Journal of Clinical Medicine, 9(8), 2406. https://doi.org/10.3390/jcm9082406 DOI: https://doi.org/10.3390/jcm9082406
Moncrieff, J. (2006). Disease mongering and drug marketing: Does the pharmaceutical industry manufacture diseases as well as drugs? EMBO Reports, 7(4), 358–361. https://doi.org/10.1038/sj.embor.7400665 DOI: https://doi.org/10.1038/sj.embor.7400665
Read, J., & Moncrieff, J. (2021). Depression: Why drugs and electricity are not the answer. Psychological Medicine, 52(8), 1401–1411. https://doi.org/10.1017/S0033291721005031 DOI: https://doi.org/10.1017/S0033291721005031
Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA, 323(9), 844–853. https://doi.org/10.1001/jama.2020.1166 DOI: https://doi.org/10.1001/jama.2020.1166
